The content of this website has been produced in line with the INLYTA® (axitinib) Summary of Product Characteristics for Great Britain.
Prescribing Information for INLYTA® (axitinib) click here. Prescribing Information for SUTENT® (sunitinib malate) click here. Adverse event reporting information can be found at the bottom of the page.
INLYTA® is an inhibitor of multiple receptor tyrosine kinases (TKIs), including vascular endothelial growth factor receptors (VEGFR) required for angiogenesis.1 Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2, making mRCC a highly vascular tumour, and underlying why the VEGF pathway continues to be a target in RCC.2
INLYTA® | 2.5-6.1 hours |
---|---|
Sorafenib | ~ 25-48 hours |
Lenvantinib | ~ 28 hours |
Everolimus | ~ 30 hours |
Cabozantinib | ~ 110 hours |
Tivozanib | 108-122.4 hours |
Sunitinib | 40-60 hours (Sunitinib) and 80-110 hours (active metabolite of Sunitinib) |
Pazopanib | 30.9 hours |
Nivolumab | 25 days |
A randomised, multicentre, Phase III trial in 723 patients with mRCC with disease progression on first-line therapy (sunitinib or cytokine), comparing the efficacy and safety of INLYTA® 5mg twice daily and sorafenib 400 mg twice daily.
1. Chow LQ and Eckhardt SG. J clin Oncol 2007;25:884-896.
2. Rini BI, et al. Lancet 2011;378(9807):1931-1939
3. INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA® Summary of Product Characteristics for Northern Ireland click here.
4. Schmidinger M, et al. Future Oncol 2018;14:861–875.
5. Sorafenib Summary of Product Characteristics. Bayer. Available at: https://www.medicines.org.uk/emc/product/226/smpc. Accessed: February 2022.
6. Lenvatinib Summary of Product Characteristics. Eisai. Available at: https://www.medicines.org.uk/emc/product/7881/smpc. Accessed: February 2022.
7. Everolimus Summary of Product Characteristics. Novartis. Available at: https://www.medicines.org.uk/emc/product/6658/smpc. Accessed: February 2022.
8. Cabozantinib Summary of Product Characteristics. Ipsen. Available at: https://www.medicines.org.uk/emc/product/4331/smpc. Accessed: February 2022.
9. Nivolumab Summary of Product Characteristics. BMS. Available at: https://www.medicines.org.uk/emc/product/6888. Accessed: February 2022.
10. Pazopanib Summary of Product Characteristics. Novartis. Available at: https://www.medicines.org.uk/emc/product/7861/smpc. Accessed: February 2022.
11. Sunitinib Summary of Product Characteristics. Pfizer. Available at: https://www.medicines.org.uk/emc/product/227/smpc. Accessed: February 2022.
12. Tivozanib Summary of Product Characteristics. EUSA. Available at: https://www.medicines.org.uk/emc/product/8995/smpc. Accessed: February 2022.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?